High Court Mifepristone Battle Goes Beyond Abortion

Denise Esposito’s commentary was included a Law360 article exploring the wider consequences of FDA v. Alliance for Hippocratic Medicine. Denise discusses how the Food and Drug Administration’s (FDA) independence in overseeing drug approvals could be affected by the case’s outcome.

"One of the big concerns that I and other members of the food and drug bar have, regardless of your position on mifepristone, is the consequence, in the long term, of a court being able to substitute its views for FDA's scientifically-driven conclusions," Denise said. “I do think that creates a really catastrophic effect on the business of the FDA, the pharmaceutical industry and the provision of healthcare services generally.”